NO20062255L - 4-anilino-3-kinolinkarbonitriler for behandling av kronisk myelogenos leukemi (CML) - Google Patents

4-anilino-3-kinolinkarbonitriler for behandling av kronisk myelogenos leukemi (CML)

Info

Publication number
NO20062255L
NO20062255L NO20062255A NO20062255A NO20062255L NO 20062255 L NO20062255 L NO 20062255L NO 20062255 A NO20062255 A NO 20062255A NO 20062255 A NO20062255 A NO 20062255A NO 20062255 L NO20062255 L NO 20062255L
Authority
NO
Norway
Prior art keywords
cml
treatment
myelogenous leukemia
chronic myelogenous
carbonitriles
Prior art date
Application number
NO20062255A
Other languages
English (en)
Norwegian (no)
Inventor
Frank Charles Boschelli
Kim Timothy Arndt
Jennifer Michele Golas
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34590192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062255(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20062255L publication Critical patent/NO20062255L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
NO20062255A 2003-11-06 2006-05-19 4-anilino-3-kinolinkarbonitriler for behandling av kronisk myelogenos leukemi (CML) NO20062255L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51781903P 2003-11-06 2003-11-06
PCT/US2004/036722 WO2005046693A1 (en) 2003-11-06 2004-11-03 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)

Publications (1)

Publication Number Publication Date
NO20062255L true NO20062255L (no) 2006-08-01

Family

ID=34590192

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062255A NO20062255L (no) 2003-11-06 2006-05-19 4-anilino-3-kinolinkarbonitriler for behandling av kronisk myelogenos leukemi (CML)

Country Status (18)

Country Link
US (2) US7417148B2 (pt)
EP (1) EP1680119A1 (pt)
JP (1) JP2007533655A (pt)
KR (1) KR20060118461A (pt)
CN (1) CN1874776A (pt)
AU (1) AU2004289243B2 (pt)
BR (1) BRPI0416289A (pt)
CA (1) CA2543163A1 (pt)
CO (1) CO5690608A2 (pt)
CR (1) CR8350A (pt)
EC (1) ECSP066548A (pt)
IL (1) IL175424A0 (pt)
MX (1) MXPA06004744A (pt)
NO (1) NO20062255L (pt)
RU (1) RU2006113691A (pt)
SG (1) SG146681A1 (pt)
WO (1) WO2005046693A1 (pt)
ZA (1) ZA200603596B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004289243B2 (en) * 2003-11-06 2010-07-22 Wyeth Llc 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
EP1896020B1 (en) * 2005-06-17 2014-08-20 The Board of Regents of The University of Texas System SKI 606 as src kinase inhibitor for treating osteolytic lesions
RU2007143434A (ru) * 2005-06-24 2009-07-27 Вайет (Us) 4-анилино-3-хинолинкарбонитрилы, подходящие для лечения раковых заболеваний
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008060283A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
SI3002009T1 (sl) * 2007-06-01 2021-09-30 Wyeth Llc Zdravljenje kronične mieloične levkemije, ki je odporna na imatinib, ki ima mutacijo 1457t>c na genu bcrabl, s pomočjo sestavine bosutinib
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
MX367055B (es) 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
WO2015123758A1 (en) 2014-02-20 2015-08-27 Apotex Inc. Bosutinib forms and preparation methods thereof
WO2016114322A1 (ja) 2015-01-13 2016-07-21 国立大学法人京都大学 筋萎縮性側索硬化症の予防及び／又は治療剤
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
EP3953450A1 (en) 2019-04-09 2022-02-16 Massachusetts Institute Of Technology A micro physiological model for neuronal and muscular diseases and disorders
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20040229880A1 (en) * 2003-02-21 2004-11-18 Wyeth 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
AU2004289243B2 (en) * 2003-11-06 2010-07-22 Wyeth Llc 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)

Also Published As

Publication number Publication date
US7417148B2 (en) 2008-08-26
AU2004289243B2 (en) 2010-07-22
JP2007533655A (ja) 2007-11-22
ECSP066548A (es) 2006-10-17
ZA200603596B (en) 2009-12-30
US20050101780A1 (en) 2005-05-12
CO5690608A2 (es) 2006-10-31
BRPI0416289A (pt) 2007-01-23
MXPA06004744A (es) 2006-07-05
CN1874776A (zh) 2006-12-06
SG146681A1 (en) 2008-10-30
IL175424A0 (en) 2008-04-13
KR20060118461A (ko) 2006-11-23
RU2006113691A (ru) 2007-12-20
US7919625B2 (en) 2011-04-05
US20100029677A1 (en) 2010-02-04
EP1680119A1 (en) 2006-07-19
CR8350A (es) 2006-10-06
AU2004289243A1 (en) 2005-05-26
CA2543163A1 (en) 2005-05-26
WO2005046693A1 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
NO20062255L (no) 4-anilino-3-kinolinkarbonitriler for behandling av kronisk myelogenos leukemi (CML)
NO20054070L (no) 4-[(2,4-diklor-5-metoksyfenyl)amino]-6-alkoksy-3-kinol inkarbonitriler for behandling av isjemisk skade.
JO2282B1 (en) Oxazole derivatives
TW200642683A (en) Heterocyclic compound
RS20050180A (en) Novel benzoimidazole derivatives useful as antiproliferative agensts
MXPA05006420A (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal.
EP1775289A4 (en) NEW IMIDAZOLIDINE DERIVATIVES
YU95102A (sh) Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
MX2009004910A (es) Compuestos sustituidos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11-b- hexahidro-2h-pirido[2,1-a] isoquinolin-2-ol y métodos que se relacionan al mismo.
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
NO20062617L (no) Anvendelse av glukosidase inhibitorer for terapi av mucovisidose
TW200727893A (en) Methods for treating sexual dysfunction
GB0413087D0 (en) Therapeutic compounds
AU2006325931A8 (en) Amine compound and use thereof for medical purposes
DK1181299T3 (da) C-2-modificerede erythromycinderivater
CA2503451A1 (en) Heterocyclic compounds and antitumor agent comprising the same as effective component
MX2010006882A (es) Derivado novedoso de catecol, composición farmaceutica que contiene el mismo, uso del derivado de catecol, y uso de la composición farmaceutica.
TW200745033A (en) Oxindole derivative as feeding control agent
BRPI0409959A (pt) uso de derivados de azetidinacarboxamida em terapia
MX2010001566A (es) Derivado de aminopirazolamida.
TW200637552A (en) Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases
WO2010100133A3 (fr) Derives indoliques pour le traitement de maladies neurodegeneratives
MXPA05013151A (es) 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application